Role of endothelial progenitor cells in cancer progression

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 1, 2014, Pages 26-39

  Moschetta, Michele ^a,b   Mishima, Yuji ^a   Sahin, Ilyas ^a   Manier, Salomon ^a   Glavey, Siobhan ^a   Vacca, Angelo ^b   Roccaro, Aldo M ^a   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Cancers; Endothelial progenitor cells; Hematological malignancies; Vasculogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN RECEPTOR; CD133 ANTIGEN; CD14 ANTIGEN; CD146 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ENDOGLIN; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CARDIOVASCULAR RISK; CELL COUNT; CELL FUNCTION; CELL ISOLATION; ENDOTHELIAL PROGENITOR CELL; FLOW CYTOMETRY; HUMAN; LEUKEMIA; METASTASIS; MOSAICISM; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLOGICAL PARAMETERS; POSTNATAL VASCULOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME; VASCULAR COOPTION; VASCULOGENIC MIMICRY; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; IN VITRO STUDY; MALIGNANT NEOPLASTIC DISEASE; SOLID TUMOR;

CANCERS; ENDOTHELIAL PROGENITOR CELLS; HEMATOLOGICAL MALIGNANCIES; VASCULOGENESIS;

ANIMALS; DISEASE PROGRESSION; ENDOTHELIAL CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS;

EID: 84898959067     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.03.005     Document Type: Review

References (157)

1. Risau W., Flamme I. Vasculogenesis. Annu. Rev. Cell Dev. Biol. 1995, 11:73-91.
2. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., Pober J.S., Wick T.M., Konkle B.A., Schwartz B.S., Barnathan E.S., McCrae K.R., Hug B.A., Schmidt A.M., Stern D.M. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
3. Yancopoulos G.D., Klagsbrun M., Folkman J. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 1998, 93:661-664.
4. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
5. Shi Q., Rafii S., Wu M.H., Wijelath E.S., Yu C., Ishida A., Fujita Y., Kothari S., Mohle R., Sauvage L.R., Moore M.A., Storb R.F., Hammond W.P. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998, 92:362-367.
6. Lin Y., Weisdorf D.J., Solovey A., Hebbel R.P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 2000, 105:71-77.
7. Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. J. Cell. Mol. Med. 2004, 8:294-300.
8. Kovacic J.C., Moore J., Herbert A., Ma D., Boehm M., Graham R.M. Endothelial progenitor cells, angioblasts, and angiogenesis - old terms reconsidered from a current perspective. Trends Cardiovasc. Med. 2008, 18:45-51.
9. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 2000, 105:17-19.
10. Janic B., Arbab A.S. The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization. ScientificWorldJournal 2010, 10:1088-1099.
11. Urbich C., Dimmeler S. Endothelial progenitor cells functional characterization. Trends Cardiovasc. Med. 2004, 14:318-322.
12. Li Calzi S., Neu M.B., Shaw L.C., Kielczewski J.L., Moldovan N.I., Grant M.B. EPCs and pathological angiogenesis: when good cells go bad. Microvasc. Res. 2010, 79:207-216.
13. Jain R.K., Duda D.G. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell 2003, 3:515-516.
14. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7:1194-1201.
15. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., Fuks Z., Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
16. Nolan D.J., Ciarrocchi A., Mellick A.S., Jaggi J.S., Bambino K., Gupta S., Heikamp E., McDevitt M.R., Scheinberg D.A., Benezra R., Mittal V. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 2007, 21:1546-1558.
17. Peters B.A., Diaz L.A., Polyak K., Meszler L., Romans K., Guinan E.C., Antin J.H., Myerson D., Hamilton S.R., Vogelstein B., Kinzler K.W., Lengauer C. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 2005, 11:261-262.
18. Rajantie I., Ilmonen M., Alminaite A., Ozerdem U., Alitalo K., Salven P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004, 104:2084-2086.
19. Machein M.R., Renninger S., de Lima-Hahn E., Plate K.H. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol. 2003, 13:582-597.
20. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
21. De Palma M., Venneri M.A., Roca C., Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 2003, 9:789-795.
22. Gothert J.R., Gustin S.E., van Eekelen J.A., Schmidt U., Hall M.A., Jane S.M., Green A.R., Gottgens B., Izon D.J., Begley C.G. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 2004, 104:1769-1777.
23. He Y., Rajantie I., Ilmonen M., Makinen T., Karkkainen M.J., Haiko P., Salven P., Alitalo K. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res. 2004, 64:3737-3740.
24. Ziegelhoeffer T., Fernandez B., Kostin S., Heil M., Voswinckel R., Helisch A., Schaper W. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ. Res. 2004, 94:230-238.
25. Mund J.A., Case J. The ontogeny of endothelial progenitor cells through flow cytometry. Curr. Opin. Hematol. 2011, 18:166-170.
26. De Palma M., Naldini L. Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy?. Biochim. Biophys. Acta 2009, 1796:5-10.
27. Basile D.P., Yoder M.C. Circulating and tissue resident endothelial progenitor cells. J. Cell. Physiol. 2014, 229:10-16.
28. Wara A.K., Croce K., Foo S., Sun X., Icli B., Tesmenitsky Y., Esen F., Rosenzweig A., Feinberg M.W. Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells: implications for ischemic cardiovascular disease. Blood 2011, 118:6461-6464.
29. Goon P.K., Lip G.Y., Boos C.J., Stonelake P.S., Blann A.D. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006, 8:79-88.
30. Fadini G.P., Losordo D., Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ. Res. 2012, 110:624-637.
31. Prater D.N., Case J., Ingram D.A., Yoder M.C. Working hypothesis to redefine endothelial progenitor cells. Leukemia 2007, 21:1141-1149.
32. Rafii S., Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 2003, 9:702-712.
33. Yoder M.C., Mead L.E., Prater D., Krier T.R., Mroueh K.N., Li F., Krasich R., Temm C.J., Prchal J.T., Ingram D.A. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109:1801-1809.
34. Ingram D.A., Mead L.E., Tanaka H., Meade V., Fenoglio A., Mortell K., Pollok K., Ferkowicz M.J., Gilley D., Yoder M.C. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004, 104:2752-2760.
35. Assmus B., Honold J., Schachinger V., Britten M.B., Fischer-Rasokat U., Lehmann R., Teupe C., Pistorius K., Martin H., Abolmaali N.D., Tonn T., Dimmeler S., Zeiher A.M. Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 2006, 355:1222-1232.
36. Bertolini F., Shaked Y., Mancuso P., Kerbel R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 2006, 6:835-845.
37. Ahrens I., Domeij H., Topcic D., Haviv I., Merivirta R.M., Agrotis A., Leitner E., Jowett J.B., Bode C., Lappas M., Peter K. Successful in vitro expansion and differentiation of cord blood derived CD34+ cells into early endothelial progenitor cells reveals highly differential gene expression. PLoS One 2011, 6:e23210.
38. Medina R.J., O'Neill C.L., Sweeney M., Guduric-Fuchs J., Gardiner T.A., Simpson D.A., Stitt A.W. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med. Genet. 2010, 3:18.
39. Hill J.M., Zalos G., Halcox J.P., Schenke W.H., Waclawiw M.A., Quyyumi A.A., Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 2003, 348:593-600.
40. Mund J.A., Ingram D.A., Yoder M.C., Case J. Endothelial progenitor cells and cardiovascular cell-based therapies. Cytotherapy 2009, 11:103-113.
41. Chao H., Hirschi K.K. Hemato-vascular origins of endothelial progenitor cells?. Microvasc. Res. 2010, 79:169-173.
42. Lancrin C., Sroczynska P., Stephenson C., Allen T., Kouskoff V., Lacaud G. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature 2009, 457:892-895.
43. Zape J.P., Zovein A.C. Hemogenic endothelium: origins, regulation, and implications for vascular biology. Semin. Cell Dev. Biol. 2011, 22:1036-1047.
44. Mund J.A., Estes M.L., Yoder M.C., Ingram D.A., Case J. Flow cytometric identification and functional characterization of immature and mature circulating endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1045-1053.
45. Goon P.K., Lip G.Y., Stonelake P.S., Blann A.D. Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia 2009, 11:771-779.
46. Yoder M.C. Human endothelial progenitor cells. Cold Spring Harb. Perspect. Med. 2012, 2:a006692.
47. Wang L., Li L., Shojaei F., Levac K., Cerdan C., Menendez P., Martin T., Rouleau A., Bhatia M. Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Immunity 2004, 21:31-41.
48. Oberlin E., Tavian M., Blazsek I., Peault B. Blood-forming potential of vascular endothelium in the human embryo. Development 2002, 129:4147-4157.
49. Vodyanik M.A., Thomson J.A., Slukvin Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures. Blood 2006, 108:2095-2105.
50. Timmermans F., Plum J., Yoder M.C., Ingram D.A., Vandekerckhove B., Case J. Endothelial progenitor cells: identity defined?. J. Cell. Mol. Med. 2009, 13:87-102.
51. Case J., Mead L.E., Bessler W.K., Prater D., White H.A., Saadatzadeh M.R., Bhavsar J.R., Yoder M.C., Haneline L.S., Ingram D.A. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp. Hematol. 2007, 35:1109-1118.
52. Timmermans F., Van Hauwermeiren F., De Smedt M., Raedt R., Plasschaert F., De Buyzere M.L., Gillebert T.C., Plum J., Vandekerckhove B. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1572-1579.
53. Peichev M., Naiyer A.J., Pereira D., Zhu Z., Lane W.J., Williams M., Oz M.C., Hicklin D.J., Witte L., Moore M.A., Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000, 95:952-958.
54. Delorme B., Basire A., Gentile C., Sabatier F., Monsonis F., Desouches C., Blot-Chabaud M., Uzan G., Sampol J., Dignat-George F. Presence of endothelial progenitor cells, distinct from mature endothelial cells, within human CD146+ blood cells. Thromb. Haemost. 2005, 94:1270-1279.
55. Duda D.G., Cohen K.S., Scadden D.T., Jain R.K. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat. Protoc. 2007, 2:805-810.
56. Heiss C., Keymel S., Niesler U., Ziemann J., Kelm M., Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J. Am. Coll. Cardiol. 2005, 45:1441-1448.
57. Fadini G.P., de Kreutzenberg S., Albiero M., Coracina A., Pagnin E., Baesso I., Cignarella A., Bolego C., Plebani M., Nardelli G.B., Sartore S., Agostini C., Avogaro A. Gender differences in endothelial progenitor cells and cardiovascular risk profile: the role of female estrogens. Arterioscler. Thromb. Vasc. Biol. 2008, 28:997-1004.
58. Braam B., Verhaar M.C. Understanding eNOS for pharmacological modulation of endothelial function: a translational view. Curr. Pharm. Des. 2007, 13:1727-1740.
59. Urbich C., Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ. Res. 2004, 95:343-353.
60. Vasa M., Fichtlscherer S., Aicher A., Adler K., Urbich C., Martin H., Zeiher A.M., Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 2001, 89:E1-E7.
61. Tepper O.M., Galiano R.D., Capla J.M., Kalka C., Gagne P.J., Jacobowitz G.R., Levine J.P., Gurtner G.C. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002, 106:2781-2786.
62. Fadini G.P., Coracina A., Baesso I., Agostini C., Tiengo A., Avogaro A., de Kreutzenberg S.V. Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Stroke 2006, 37:2277-2282.
63. Bielak L.F., Horenstein R.B., Ryan K.A., Sheedy P.F., Rumberger J.A., Tanner K., Post W., Mitchell B.D., Shuldiner A.R., Peyser P.A. Circulating CD34+ cell count is associated with extent of subclinical atherosclerosis in asymptomatic Amish men, independent of 10-year Framingham risk. Clin. Med. Cardiol. 2009, 3:53-60.
64. Kunz G.A., Liang G., Cuculi F., Gregg D., Vata K.C., Shaw L.K., Goldschmidt-Clermont P.J., Dong C., Taylor D.A., Peterson E.D. Circulating endothelial progenitor cells predict coronary artery disease severity. Am. Heart J. 2006, 152:190-195.
65. Lau K.K., Chan Y.H., Yiu K.H., Li S.W., Tam S., Lau C.P., Kwong Y.L., Tse H.F. Burden of carotid atherosclerosis in patients with stroke: relationships with circulating endothelial progenitor cells and hypertension. J. Hum. Hypertens. 2007, 21:445-451.
66. Hughes A.D., Coady E., Raynor S., Mayet J., Wright A.R., Shore A.C., Kooner J.S., Thom S.A., Chaturvedi N. Reduced endothelial progenitor cells in European and South Asian men with atherosclerosis. Eur. J. Clin. Invest. 2007, 37:35-41.
67. Xiao Q., Kiechl S., Patel S., Oberhollenzer F., Weger S., Mayr A., Metzler B., Reindl M., Hu Y., Willeit J., Xu Q. Endothelial progenitor cells, cardiovascular risk factors, cytokine levels and atherosclerosis - results from a large population-based study. PLoS One 2007, 2:e975.
68. Shintani S., Murohara T., Ikeda H., Ueno T., Honma T., Katoh A., Sasaki K., Shimada T., Oike Y., Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001, 103:2776-2779.
69. Gill M., Dias S., Hattori K., Rivera M.L., Hicklin D., Witte L., Girardi L., Yurt R., Himel H., Rafii S. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ. Res. 2001, 88:167-174.
70. Kalka C., Masuda H., Takahashi T., Kalka-Moll W.M., Silver M., Kearney M., Li T., Isner J.M., Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3422-3427.
71. Kawamoto A., Gwon H.C., Iwaguro H., Yamaguchi J.I., Uchida S., Masuda H., Silver M., Ma H., Kearney M., Isner J.M., Asahara T. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001, 103:634-637.
72. Leistner D.M., Fischer-Rasokat U., Honold J., Seeger F.H., Schachinger V., Lehmann R., Martin H., Burck I., Urbich C., Dimmeler S., Zeiher A.M., Assmus B. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin. Res. Cardiol. 2011, 100:925-934.
73. Schachinger V., Assmus B., Britten M.B., Honold J., Lehmann R., Teupe C., Abolmaali N.D., Vogl T.J., Hofmann W.K., Martin H., Dimmeler S., Zeiher A.M. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J. Am. Coll. Cardiol. 2004, 44:1690-1699.
74. Assmus B., Schachinger V., Teupe C., Britten M., Lehmann R., Dobert N., Grunwald F., Aicher A., Urbich C., Martin H., Hoelzer D., Dimmeler S., Zeiher A.M. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002, 106:3009-3017.
75. Stamm C., Westphal B., Kleine H.D., Petzsch M., Kittner C., Klinge H., Schumichen C., Nienaber C.A., Freund M., Steinhoff G. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003, 361:45-46.
76. Jara L.J., Medina G., Vera-Lastra O., Amigo M.C. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun. Rev. 2006, 5:195-201.
77. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., Jara L.J., Abu-Shakra M., Meroni P.L., Sherer Y. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005, 112:3337-3347.
78. Roman M.J., Salmon J.E. Cardiovascular manifestations of rheumatologic diseases. Circulation 2007, 116:2346-2355.
79. Westerweel P.E., Verhaar M.C. Endothelial progenitor cell dysfunction in rheumatic disease. Nat. Rev. Rheumatol. 2009, 5:332-340.
80. Kopp H.G., Avecilla S.T., Hooper A.T., Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology 2005, 20:349-356.
81. Khakoo A.Y., Finkel T. Endothelial progenitor cells. Annu. Rev. Med. 2005, 56:79-101.
82. Kopp H.G., Ramos C.A., Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr. Opin. Hematol. 2006, 13:175-181.
83. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., Isner J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999, 18:3964-3972.
84. Hattori K., Dias S., Heissig B., Hackett N.R., Lyden D., Tateno M., Hicklin D.J., Zhu Z., Witte L., Crystal R.G., Moore M.A., Rafii S. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 2001, 193:1005-1014.
85. Rafii S., Meeus S., Dias S., Hattori K., Heissig B., Shmelkov S., Rafii D., Lyden D. Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin. Cell Dev. Biol. 2002, 13:61-67.
86. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N.R., Crystal R.G., Besmer P., Lyden D., Moore M.A., Werb Z., Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002, 109:625-637.
87. Ribatti D., Nico B., Crivellato E., Vacca A. Endothelial progenitor cells in health and disease. Histol. Histopathol. 2005, 20:1351-1358.
88. Takahashi T., Kalka C., Masuda H., Chen D., Silver M., Kearney M., Magner M., Isner J.M., Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 1999, 5:434-438.
89. Mohle R., Bautz F., Rafii S., Moore M.A., Brugger W., Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998, 91:4523-4530.
90. Schioppa T., Uranchimeg B., Saccani A., Biswas S.K., Doni A., Rapisarda A., Bernasconi S., Saccani S., Nebuloni M., Vago L., Mantovani A., Melillo G., Sica A. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. 2003, 198:1391-1402.
91. Jin D.K., Shido K., Kopp H.G., Petit I., Shmelkov S.V., Young L.M., Hooper A.T., Amano H., Avecilla S.T., Heissig B., Hattori K., Zhang F., Hicklin D.J., Wu Y., Zhu Z., Dunn A., Salari H., Werb Z., Hackett N.R., Crystal R.G., Lyden D., Rafii S. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat. Med. 2006, 12:557-567.
92. Yamaguchi J., Kusano K.F., Masuo O., Kawamoto A., Silver M., Murasawa S., Bosch-Marce M., Masuda H., Losordo D.W., Isner J.M., Asahara T. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003, 107:1322-1328.
93. Duda D.G., Cohen K.S., Kozin S.V., Perentes J.Y., Fukumura D., Scadden D.T., Jain R.K. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 2006, 107:2774-2776.
94. Gao D., Nolan D.J., Mellick A.S., Bambino K., McDonnell K., Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008, 319:195-198.
95. Ruzinova M.B., Schoer R.A., Gerald W., Egan J.E., Pandolfi P.P., Rafii S., Manova K., Mittal V., Benezra R. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003, 4:277-289.
96. Purhonen S., Palm J., Rossi D., Kaskenpaa N., Rajantie I., Yla-Herttuala S., Alitalo K., Weissman I.L., Salven P. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:6620-6625.
97. de Candia P., Solit D.B., Giri D., Brogi E., Siegel P.M., Olshen A.B., Muller W.J., Rosen N., Benezra R. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12337-12342.
98. Sikder H., Huso D.L., Zhang H., Wang B., Ryu B., Hwang S.T., Powell J.D., Alani R.M. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003, 4:291-299.
99. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 2010, 120:694-705.
100. Gao D., Nolan D., McDonnell K., Vahdat L., Benezra R., Altorki N., Mittal V. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim. Biophys. Acta 2009, 1796:33-40.
101. Shaked Y., Bertolini F., Man S., Rogers M.S., Cervi D., Foutz T., Rawn K., Voskas D., Dumont D.J., Ben-David Y., Lawler J., Henkin J., Huber J., Hicklin D.J., D'Amato R.J., Kerbel R.S. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005, 7:101-111.
102. Richter-Ehrenstein C., Rentzsch J., Runkel S., Schneider A., Schonfelder G. Endothelial progenitor cells in breast cancer patients. Breast Cancer Res. Treat. 2007, 106:343-349.
103. Nowak K., Rafat N., Belle S., Weiss C., Hanusch C., Hohenberger P., Beck G. Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease. Eur. J. Cardiothorac. Surg. 2010, 37:758-763.
104. Ha X., Zhao M., Zhao H., Peng J., Deng Z., Dong J., Yang X., Zhao Y., Ju J. Identification and clinical significance of circulating endothelial progenitor cells in gastric cancer. Biomarkers 2013, 18:487-492.
105. Kim Y.B., Chung Y.W., Bae H.S., Lee J.K., Lee N.W., Lee K.W., Song J.Y. Circulating endothelial progenitor cells in gynaecological cancer. J. Int. Med. Res. 2013, 41:293-299.
106. Su Y., Zheng L., Wang Q., Li W., Cai Z., Xiong S., Bao J. Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer. J. Exp. Clin. Cancer Res. 2010, 29:27.
107. Ho J.W., Pang R.W., Lau C., Sun C.K., Yu W.C., Fan S.T., Poon R.T. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006, 44:836-843.
108. Zheng P.P., Hop W.C., Luider T.M., Sillevis Smitt P.A., Kros J.M. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann. Neurol. 2007, 62:40-48.
109. Shaked Y., Ciarrocchi A., Franco M., Lee C.R., Man S., Cheung A.M., Hicklin D.J., Chaplin D., Foster F.S., Benezra R., Kerbel R.S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313:1785-1787.
110. Taylor M., Billiot F., Marty V., Rouffiac V., Cohen P., Tournay E., Opolon P., Louache F., Vassal G., Laplace-Builhe C., Vielh P., Soria J.C., Farace F. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov. 2012, 2:434-449.
111. De Palma M., Nucera S. Circulating endothelial progenitors and tumor resistance to vascular-targeting therapies. Cancer Discov. 2012, 2:395-397.
112. Welford A.F., Biziato D., Coffelt S.B., Nucera S., Fisher M., Pucci F., Di Serio C., Naldini L., De Palma M., Tozer G.M., Lewis C.E. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest. 2011, 121:1969-1973.
113. Shaked Y., Henke E., Roodhart J.M., Mancuso P., Langenberg M.H., Colleoni M., Daenen L.G., Man S., Xu P., Emmenegger U., Tang T., Zhu Z., Witte L., Strieter R.M., Bertolini F., Voest E.E., Benezra R., Kerbel R.S. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14:263-273.
114. Roodhart J.M., Langenberg M.H., Vermaat J.S., Lolkema M.P., Baars A., Giles R.H., Witteveen E.O., Voest E.E. Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia 2010, 12:87-94.
115. Moschetta M., Pretto F., Berndt A., Galler K., Richter P., Bassi A., Oliva P., Micotti E., Valbusa G., Schwager K., Kaspar M., Trachsel E., Kosmehl H., Bani M.R., Neri D., Giavazzi R. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res. 2012, 72:1814-1824.
116. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4:423-436.
117. Bertolini F., Paul S., Mancuso P., Monestiroli S., Gobbi A., Shaked Y., Kerbel R.S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003, 63:4342-4346.
118. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
119. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., Capla J.M., Galiano R.D., Levine J.P., Gurtner G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 2004, 10:858-864.
120. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., Song H., Vandenberg S., Johnson R.S., Werb Z., Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
121. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., Ancukiewicz M., Mrugala M.M., Plotkin S., Drappatz J., Louis D.N., Ivy P., Scadden D.T., Benner T., Loeffler J.S., Wen P.Y., Jain R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
122. Willett C.G., Boucher Y., Duda D.G., di Tomaso E., Munn L.L., Tong R.T., Kozin S.V., Petit L., Jain R.K., Chung D.C., Sahani D.V., Kalva S.P., Cohen K.S., Scadden D.T., Fischman A.J., Clark J.W., Ryan D.P., Zhu A.X., Blaszkowsky L.S., Shellito P.C., Mino-Kenudson M., Lauwers G.Y. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 2005, 23:8136-8139.
123. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
124. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van Rooijen N., Giacca M., Stassen J.M., Dewerchin M., Collen D., Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
125. Grunewald M., Avraham I., Dor Y., Bachar-Lustig E., Itin A., Jung S., Chimenti S., Landsman L., Abramovitch R., Keshet E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006, 124:175-189.
126. Gunsilius E., Duba H.C., Petzer A.L., Kahler C.M., Grunewald K., Stockhammer G., Gabl C., Dirnhofer S., Clausen J., Gastl G. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 2000, 355:1688-1691.
127. Streubel B., Chott A., Huber D., Exner M., Jager U., Wagner O., Schwarzinger I. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 2004, 351:250-259.
128. Rigolin G.M., Fraulini C., Ciccone M., Mauro E., Bugli A.M., De Angeli C., Negrini M., Cuneo A., Castoldi G. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006, 107:2531-2535.
129. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., Zhao R.C. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood 2005, 105:2733-2740.
130. Otten J., Schultze A., Schafhausen P., Otterstetter S., Dierlamm J., Bokemeyer C., Brummendorf T.H., Fiedler W., Loges S. Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative. Br. J. Haematol. 2008, 142:115-118.
131. Oppliger Leibundgut E., Horn M.P., Brunold C., Pfanner-Meyer B., Marti D., Hirsiger H., Tobler A., Zwicky C. Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. Haematologica 2006, 91:1465-1472.
132. Braunstein M., Ozcelik T., Bagislar S., Vakil V., Smith E.L., Dai K., Akyerli C.B., Batuman O.A. Endothelial progenitor cells display clonal restriction in multiple myeloma. BMC Cancer 2006, 6:161.
133. Ribatti D., Nico B., Ranieri G., Specchia G., Vacca A. The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 2013, 15:231-238.
134. Monestiroli S., Mancuso P., Burlini A., Pruneri G., Dell'Agnola C., Gobbi A., Martinelli G., Bertolini F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001, 61:4341-4344.
135. Igreja C., Courinha M., Cachaco A.S., Pereira T., Cabecadas J., da Silva M.G., Dias S. Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients. Haematologica 2007, 92:469-477.
136. Kini A.R., Kay N.E., Peterson L.C. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000, 14:1414-1418.
137. Rigolin G.M., Maffei R., Rizzotto L., Ciccone M., Sofritti O., Daghia G., Cibien F., Cavazzini F., Marasca R., Cuneo A. Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance. Cancer 2010, 116:1926-1937.
138. Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 1997, 150:815-821.
139. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95:309-313.
140. Shih T.T., Hou H.A., Liu C.Y., Chen B.B., Tang J.L., Chen H.Y., Wei S.Y., Yao M., Huang S.Y., Chou W.C., Hsu S.C., Tsay W., Yu C.W., Hsu C.Y., Tien H.F., Yang P.C. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 2009, 113:3161-3167.
141. Padro T., Ruiz S., Bieker R., Burger H., Steins M., Kienast J., Buchner T., Berdel W.E., Mesters R.M. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000, 95:2637-2644.
142. Wierzbowska A., Robak T., Krawczynska A., Wrzesien-Kus A., Pluta A., Cebula B., Smolewski P. Circulating endothelial cells in patients with acute myeloid leukemia. Eur. J. Haematol. 2005, 75:492-497.
143. Wierzbowska A., Robak T., Krawczynska A., Pluta A., Wrzesien-Kus A., Cebula B., Robak E., Smolewski P. Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients. Ann. Hematol. 2008, 87:97-106.
144. Keith T., Araki Y., Ohyagi M., Hasegawa M., Yamamoto K., Kurata M., Nakagawa Y., Suzuki K., Kitagawa M. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br. J. Haematol. 2007, 137:206-215.
145. Della Porta M.G., Malcovati L., Rigolin G.M., Rosti V., Bonetti E., Travaglino E., Boveri E., Galli A., Boggi S., Ciccone M., Pramparo T., Mazzini G., Invernizzi R., Lazzarino M., Cazzola M. Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes. Leukemia 2008, 22:530-537.
146. Vacca A., Ribatti D., Roncali L., Ranieri G., Serio G., Silvestris F., Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 1994, 87:503-508.
147. Rajkumar S.V., Mesa R.A., Fonseca R., Schroeder G., Plevak M.F., Dispenzieri A., Lacy M.Q., Lust J.A., Witzig T.E., Gertz M.A., Kyle R.A., Russell S.J., Greipp P.R. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin. Cancer Res. 2002, 8:2210-2216.
148. Zhang H., Vakil V., Braunstein M., Smith E.L., Maroney J., Chen L., Dai K., Berenson J.R., Hussain M.M., Klueppelberg U., Norin A.J., Akman H.O., Ozcelik T., Batuman O.A. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005, 105:3286-3294.
149. Bhaskar A., Gupta R., Kumar L., Sharma A., Sharma M.C., Kalaivani M., Thakur S.C. Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma. Leuk. Lymphoma 2012, 53:635-640.
150. Udi J., Wider D., Kleber M., Ihorst G., Muller A., Wasch R., Engelhardt M. Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: association with disease characteristics and variation in different cell compartments. Leuk. Res. 2011, 35:1265-1268.
151. Moschetta M., Mishima Y., Aljawai Y., et al. Bone marrow mobilization of endothelial progenitor cells represents an early pathogenic event during multiple myeloma progression. Blood (ASH Ann. Meet. Abstr.) 2013, 122:680.
152. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
153. Hendrix M.J., Seftor E.A., Hess A.R., Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 2003, 3:411-421.
154. Chang Y.S., di Tomaso E., McDonald D.M., Jones R., Jain R.K., Munn L.L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14608-14613.
155. Yu D.D., Liu H.L., Bai Y.L., Wu B., Chen W.H., Ren J.H., Zhang T., Yang K.Y., Wu G. Correlation between increased circulating endothelial progenitor cells and stage of non-Hodgkin lymphoma. J. Huazhong Univ. Sci. Technol. Med. Sci. 2013, 33:284-287.
156. Cortelezzi A., Fracchiolla N.S., Mazzeo L.M., Silvestris I., Pomati M., Somalvico F., Bertolini F., Mancuso P., Pruneri G.C., Gianelli U., Pasquini M.C., Cortiana M., Deliliers G.L. Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leuk. Lymphoma 2005, 46:1345-1351.
157. Massa M., Rosti V., Ramajoli I., Campanelli R., Pecci A., Viarengo G., Meli V., Marchetti M., Hoffman R., Barosi G. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J. Clin. Oncol. 2005, 23:5688-5695.